Investor Relations

Latest Financial Results

Q2 2021

Quarter Ended Jun 30, 2021

Latest Annual Filing

Fiscal Year Ended Dec 31, 2020

View Filing

Stock Information

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

BioXcel Therapeutics Presentation

BioXcel Therapeutics Presentation

Download BioXcel Therapeutics Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

BioXcel Therapeutics, Inc.
555 Long Wharf Drive
12th Floor
New Haven, CT 06511
United States
T: 475-238-6837
info@bioxceltherapeutics.com

Investor Relations

FTI Consulting
Matt Ventimiglia
T: 212-850-5624
matthew.ventimiglia@fticonsulting.com

Transfer Agent

American Stock Transfer and Trust